The NCCN Soft Tissue Sarcoma Guidelines include a subsection about treatment
recommendations for gastrointestinal stromal tumors (GISTs). The standard of practice rapidly …

Background The management of gastrointestinal stromal tumors (GIST) has evolved very
rapidly in the last 4 years. The objectives of this international consensus meeting were to …

Although kinase inhibitors raise hope for people with cancer, patients and their clinicians
are commonly confronted with the cutaneous side-effects that are associated with the use of …

Background Pazopanib, a multitargeted tyrosine kinase inhibitor, has single-agent activity in
patients with advanced non-adipocytic soft-tissue sarcoma. We investigated the effect of …

Background Until now, only imatinib and sunitinib have proven clinical benefit in patients with
gastrointestinal stromal tumours (GIST), but almost all metastatic GIST eventually develop …

CD4 + CD25 + regulatory T cells are involved in the prevention of autoimmune diseases and
in tumor-induced tolerance. We previously demonstrated in tumor-bearing rodents that one …

A recent randomized EORTC phase III trial, comparing two doses of imatinib in patients with
advanced gastrointestinal stromal tumours (GISTs), reported dose dependency for …

Lymphopenia is frequent in advanced cancers and predicts the toxicity of chemotherapy. Its
effect on relapse and survival is uncertain. Its prognostic value for survival was analyzed in …

Background A non-randomised, phase 2 study showed activity and tolerability of eribulin in
advanced or metastatic soft-tissue sarcoma. In this phase 3 study, we aimed to compare …

Purpose Given the importance of angiogenesis in soft tissue sarcoma (STS), pazopanib, an
oral angiogenesis inhibitor that targets vascular endothelial growth factor receptor and …